Specificity of SARS-CoV-2 Antibody Detection Assays against S and N Proteins among Pre-COVID-19 Sera from Patients with Protozoan and Helminth Parasitic Infections

Cedric P. Yansouni,[a,b,c,d] Jesse Papenburg,[c,d,e,f] Matthew P. Cheng,[b,c,d] Rachel Corsini,[d] Chelsea Caya,[d] Fabio Vasquez Camargo,[g] Luke B. Harrison,[b,c] Gerasimos Zaharatos,[c] Philippe Büscher,[h] Babacar Faye,[i] Magatte Ndiaye,[i] Greg Matlashewski,[j] Momar Ndao[b,d,g,j]

[a]J.D. MacLean Centre for Tropical Diseases, McGill University, Montreal, Quebec, Canada

[b]Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada

[c]Division of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montreal – McGill University Health Centre, Montreal, Quebec, Canada

[d]McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada

[e]Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children's Hospital, Montreal, Quebec, Canada

[f]Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada

[g]National Reference Centre for Parasitology, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

[h]Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

[i]Faculty of Medicine, Department of Parasitology, University of Cheikh Anta Diop, Dakar, Senegal

[j]Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada

Cedric P. Yansouni and Momar Ndao contributed equally to this article.

ABSTRACT We aimed to assess the specificity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody detection assays among people with tissue-borne parasitic infections. We tested three SARS-CoV-2 antibody-detection assays (cPass SARS-CoV-2 neutralization antibody detection kit [cPass], Abbott SARS-CoV-2 IgG assay [Abbott Architect], and Standard Q COVID-19 IgM/IgG combo rapid diagnostic test [SD RDT IgM/SD RDT IgG]) among 559 pre-COVID-19 seropositive sera for several parasitic infections. The specificity of assays was 95 to 98% overall. However, lower specificity was observed among sera from patients with protozoan infections of the reticuloendothelial system, such as human African trypanosomiasis (Abbott Architect; 88% [95% CI, 75 to 95]) and visceral leishmaniasis (SD RDT IgG; 80% [95% CI, 30 to 99]), and from patients with recent malaria in areas of Senegal where malaria is holoendemic (ranging from 91% for Abbott Architect and SD RDT IgM to 98 to 99% for cPass and SD RDT IgG). For specimens from patients with evidence of past or present helminth infection overall, test specificity estimates were all ≥96%. Sera collected from patients clinically suspected of parasitic infections that tested negative for these infections yielded a specificity of 98 to 100%. The majority (>85%) of false-positive results were positive by only one assay. The specificity of SARS-CoV-2 serological assays among sera from patients with tissue-borne parasitic infections was below the threshold required for decisions about individual patient care. Specificity is markedly increased by the use of confirmatory testing with a second assay. Finally, the SD RDT IgG proved similarly specific to laboratory-based assays and provides an option in low-resource settings when detection of anti-SARS-CoV-2 IgG is indicated.

KEYWORDS SARS-CoV-2, COVID-19, diagnostic accuracy, antibody test, serology, parasitic infections, malaria, kinetoplastid infections, protozoan infections, helminth infections, *Strongyloides*, *Schistosoma*, filaria, *Trichinella*, neglected tropical diseases

Address correspondence to Cedric P. Yansouni, cedric.yansouni@mcgill.ca, or Momar Ndao, momar.ndao@mcgill.ca.

Specific indications for serological testing for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) have been reviewed in detail (1, 2). Despite a rapid increase

TABLE 1 Origin of pre-COVID-19 specimens

Parasitic diagnosis	Origin	Testing details
Imported malaria[a]	Specimens from clinical suspects submitted to NRCP[b] (n = 143)	Patients in whom a separate whole blood specimen submitted to NRCP was positive for malaria by PCR[c] within 14 days
Hyperendemic malaria[a]	Specimens from clinical suspects submitted to the Department of Parasitology, University of Cheikh Anta Diop, Dakar, Senegal (n = 100)	Confirmed active or recent malaria by microscopy or RDT[d]
Visceral leishmaniasis (Leishmania donovani complex)[a]	Specimens from clinical suspects submitted to NRCP (n = 5)	Direct agglutination test
Human African trypanosomiasis (Trypanosoma brucei gambiense)[a]	Specimens from clinical suspects submitted to ITM[e] (n = 40) or NRCP (n = 2)	Card agglutination test for trypanosomiasis
T. cruzi seropositivity	Specimens from clinical suspects submitted to NRCP (n = 49)	Crude T. cruzi epimastigotes antigen ELISA[f]
Strongyloides stercoralis seropositivity	Specimens from clinical suspects submitted to NRCP (n = 50)	Recombinant Strongyloides antigen (NIE[g]) ELISA
Schistosoma sp. seropositivity	Specimens from clinical suspects submitted to NRCP (n = 40)	Crude Schistosoma mansoni and Schistosoma haematobium antigens ELISA
Filaria sp. seropositivity	Specimens from clinical suspects submitted to NRCP (n = 40)	Crude Brugia malayi antigen ELISA
Trichinella sp. seropositivity[a]	Specimens from clinical suspects submitted to NRCP (n = 30)	Crude Trichinella spiralis antigen ELISA
Sera from parasite suspects negative for all above pathogens	Specimens from clinical suspects submitted to NRCP (n = 60)	Sera from parasite suspects negative for all above pathogens

[a]These specimens were drawn from patients clinically suspected of active disease for the purpose of diagnosis, as opposed to screening of asymptomatic individuals.
[b]NRCP, National Reference Centre for Parasitology.
[c]PCR, polymerase chain reaction.
[d]RDT, rapid diagnostic test.
[e]ITM, Institute of Tropical Medicine Antwerp.
[f]ELISA, enzyme-linked immunosorbent assay.
[g]NIE, recombinant immunodiagnostic protein antigen derived from the L3 infective stage of Strongyloides stercoralis.

in the number and availability of serological assays detecting anti-SARS-CoV-2 antibodies, critical knowledge gaps remain regarding cross-reactivity of assays with sera from patients with noncoronavirus infectious agents.

In tropical regions of the world, several infections that dominate the local epidemiology of acute fever syndromes may cause nonspecific cross-reactivity with a wide range of serological assays (3–7). The mechanisms underlying cross-reactivity include infection of the reticuloendothelial system by several protozoans, with associated polyclonal B-lymphocyte proliferation (6, 7), and the broad diversity of antibodies elicited by various helminth infections (8). These infections include many neglected tropical diseases (NTDs) and malaria, for which the combined global burden exceeds 1.6 billion cases annually, with 3.8 billion at risk (9, 10). Simultaneously, three of the four countries with the largest total number of deaths attributed to COVID-19 are currently Brazil, India, and Mexico (Center for Systems Science and Engineering at Johns Hopkins University, COVID-19 dashboard, https://coronavirus.jhu.edu/map.html), all of which suffer a high burden of NTDs or malaria. As a result of this overlapping incidence, the specificity of SARS-CoV-2 serological tests may be different in countries where these infections are endemic compared to that in high-income countries. We aimed to assess the specificity of three SARS-CoV-2 antibody-detection assays against either the S or the N protein among a large collection of pre-COVID-19 sera from patients who were either ill with microbiologically proven malaria or seropositive for other tissue-borne parasitic infections.

MATERIALS AND METHODS

Ethics. This work was approved by the Research Ethics Boards of the Research Institute of the McGill University Health Centre (RI-MUHC number 2021-7246).

Sources of specimens tested. Specimens were well-characterized sera collected prior to July 2019 from patients with active or recent malaria imported to Canada, with active or recent malaria in an area where malaria is hyperendemic (Senegal), from clinical suspects for human African trypanosomiasis and for visceral leishmaniasis, from seropositives for Chagas disease, for Strongyloides sp., for Schistosoma sp., for filaria species, and for Trichinella sp. and from negative controls for whom tissue-borne parasitic infection was suspected but antibody testing was negative. The source and types of specimens are detailed in Table 1.

SARS-CoV-2 antibody testing. Three different SARS-CoV-2 antibody-detection assays were selected to assess the specificity of assays that detect different analytes, including anti-SARS-CoV-2 N-protein IgM, anti-SARS-CoV-2 N-protein IgG, and anti-receptor-binding domain (RBD) blocking antibodies of all immunoglobulin subclasses. We selected high-throughput assays for antibodies against N protein and RDB. In addition, among the three assays evaluated, we included an immunochromatographic rapid diagnostic test (RDT) that can be performed in low-resource settings and available from a quality-assured manufacturer with an international presence to enhance the relevance of this evaluation to the low-resource settings where NTDs and malaria are common. The RDT provides a separate readout for anti-N protein IgM and anti-N protein IgG, which we considered independently in our analysis.

Culture-free neutralization antibody detection assay (cPass). The cPass SARS-CoV-2 neutralization antibody detection kit (cPass) (Genscript, Piscataway, NJ) uses a blocking ELISA format with human ACE-2 receptor molecules coated on an ELISA plate (18, 21). Human sera preincubated with labeled epitopes of the RBD on S1 proteins are then transferred to the plate. This blocking ELISA serves as a surrogate assay to determine the capacity of human sera to block the interaction between the Spike fusion protein (through its RBD) and its cellular receptor ACE-2. The analyte detected is an anti-RBD blocking Ab of all subclasses. All the specimens, including positive and negative controls provided with the kit, were processed according to the manufacturer's instructions and included a 10× dilution factor of the primary specimen. All specimens and controls were tested in duplicate, and the percentage of inhibition calculation was based on the mean of OD for each duplicate. A cutoff 30% inhibition for SARS-CoV-2 neutralizing antibody detection was used to determine the presence of neutralizing antibodies, based on the manufacturer's instructions for use.

Abbott SARS-CoV-2 IgG assay (Abbott Architect). The Abbott SARS-CoV-2 IgG assay (Abbott Architect, Abbott Laboratories, Abbott Park, IL), which detects IgG against SARS-CoV-2 N protein, was performed on the Architect i2000sr platform according to the manufacturer's instructions. Specimens were thawed on the day of testing and were centrifuged at 10,000 × g for 10 min prior to each run. A sample-to-stored calibrator index (S/C) cutoff value of 1.4 was used for positive results, according to the manufacturer's recommendations.

Standard Q COVID-19 IgM/IgG Combo Rapid Test (SD RDT IgM and SD RDT IgG). The Standard Q COVID-19 IgM/IgG combo rapid test (SD BioSensor, Gyeonggi-do, Republic of Korea) is a rapid immunochromatography diagnostic test (RDT) for the qualitative detection of specific IgM (SD RDT IgM) and IgG (SD RDT IgG) against SARS-CoV-2 N protein on two separate test lines. The RDT provides a separate readout for anti-N protein IgM and anti-N protein IgG, which we considered independently in our analysis. Serum specimens were processed according to the manufacturer's instructions. Briefly, 10 μl of serum were applied to the specimen well of the test device. Three drops (90 μl) of buffer were added immediately and vertically into the same specimen well. The test results were read visually at within 15 min. According to the manufacturer, any visible band was considered a positive result. To facilitate analysis of positive test results, we further classified the intensity of test bands according to a standard color intensity scale provided by the manufacturer as follows: no signal (score of 0), barely visible but present (score of 1), low intensity (faint but definitively positive; score of 2), and medium to high intensity (score of 3) (Fig. 1).

Statistical analysis. Because all specimens were collected in the prepandemic era, prior to July 2019, all positive results for SARS-CoV-2 antibodies were considered false positives. The primary outcome calculated was test specificity and its corresponding 95% confidence intervals (95% CI), estimated according to a binomial distribution using the Wilson score method with Yate's continuity correction as appropriate. The secondary outcome was relative risk (RR) for a false positive and the associated 95% CI. Both were estimated according to (i) positivity status for each parasite of interest and (ii) SARS-CoV-2 target antigen tested. Statistical analyses were performed using R version 3.5.2 (R Core Team, Vienna, Austria). Area-proportional Venn diagrams were generated using eulerAPE version 3 (22).

RESULTS

Specificity of three commercial SARS-CoV-2 serological assays. The origin and characteristics of pre-COVID-19 specimens are reported in Table 1. Table 2 presents test specificity across the 559 samples tested. Overall, the point estimates of specificity of the cPass (10 of 559: 98%; 95% CI, 97 to 99) and SD rapid diagnostic test (RDT) IgG results (15 of 559: 97%; 95% CI, 96 to 98) were similar to those for Abbott Architect (26 of 548: 95%; 95% CI, 93 to 97) and SD RDT IgM result (30/559: 95%; 95% CI, 92 to 96).

For specimens from patients with evidence of blood- or tissue-invasive protozoan infections overall, test specificity was as follows: cPass (4 of 339: 99%; 95% CI, 97 to 99), SD RDT IgG (10 of 339: 97%; 95% CI, 95 to 98), Abbott Architect (19 of 328: 94%; 95% CI, 91 to 96), and SD RDT IgM results (23 of 339: 93%; 95% CI, 90 to 95). For specimens from Senegalese patients with malaria, specificity ranged from 91% (95% CI, 84 to 95) for the Abbott Architect and SD RDT IgM results to 99% (95% CI, 94 to 100) for the SD RDT IgG results. For specimens from travelers with imported malaria, test specificity ranged between 92 and 99%. Among sera positive for anti-*Leishmania* sp. and anti-*Trypanosoma cruzi* antibodies, cPass, Abbott Architect, and SD RDT IgM displayed 100% specificity. However, the SD RDT IgG result yielded specificities of 80% (95% CI, 30 to 99) and 92% (95% CI, 81 to 97) against visceral leishmaniasis and human American trypanosomiasis, respectively. The SD

FIG 1 Categorization for SD RDT band intensity, based on a standard color scale provided by SD Biosensor. A score of 0 indicates no signal; 1 indicates barely visible but present (corresponding to R1 to R6 on the standard scale); 2 indicates low intensity (i.e., faint but definitively positive, corresponding to R7 to R12 on the standard scale); and 3 indicates medium to high intensity (corresponding to R13 to R21 on the standard scale). The upper row shows the standard color scale provided by the manufacturer. The lower row shows actual RDTs used in the present study, photographed on the same day under standardized lighting conditions. The illustrative test line is shown in the dashed rectangle.

RDT IgG result did not generate any false positives when used against human African trypanosomiasis specimens, whereas specificity of 88% (95% CI, 75 to 95) was observed for Abbott Architect.

For specimens from patients with evidence of past or present helminth infection overall, test specificity estimates were all ≥96%. When evaluated against specimens seropositive for *Strongyloides* sp. (n = 50) and *Trichinella* sp. (n = 30), specificities ranged from 96 to 98%. Test specificity assessed against specimens seropositive for filarial species (n = 40) ranged from 92 to 95% and from 92 to 97% against specimens seropositive for *Schistosoma* sp. (n = 40).

Sera collected from patients clinically suspected of parasitic infections that tested negative were also assessed. cPass yielded a specificity of 98% (1 false positive out of 60), whereas Abbott Architect, SD RDT IgG, and SD RDT IgM showed a specificity of 100%.

To allow statistical comparisons across the entire group, we computed the relative risk (RR) and 95% CI of a false-positive result by assay and target analyte, according to specimen origin (Table 3). Compared to cPass, the risk of a false-positive SARS-CoV-2 result was higher for the Architect and the SD RDT IgM result overall across all specimens (RR, 2.65; 95% CI, 1.29 to 5.45; and RR, 3.00; 95% CI, 1.48 to 6.08, respectively), for malaria specimens overall (RR, 4.89; 95% CI, 1.42 to 16.79; and RR, 7.00; 95% CI, 2.11 to 23.16), and for protozoan infections overall (RR, 4.91; 95% CI, 1.69 to 14.28; and RR, 5.75; 95% CI, 2.01 to 16.45). No significant differences were seen across assays for helminthic infections. SD RDT IgG relative risk of false positive was not significantly different from that of cPass for any of the specimen origins.

Characterization of false-positive results in terms of categorical agreement and signal intensity across serological assays. Categorical agreement between commercial serological assays for the detection of SARS-CoV-2 is depicted in Fig. 2. The majority (>85%) of false-positive results were positive by only one of the assays tested. When comparing cPass, Abbott Architect, and SD RDT IgG (Fig. 2A); cPass, Abbott Architect, and SD RDT IgM

TABLE 2 Diagnostic specificity of three commercial serological assays for detection of SARS-CoV-2

Pre-COVID specimen origin	No.	Assay	Analyte detected	FP[a]	TN[b]	Specificity (95% CI) (%)[c]
Confirmed active or recent malaria by microscopy or RDT (Senegal, area where malaria is endemic)[d]	100	cPass[e]	Anti-RBD[f] blocking Ab,[g] all subclasses	2	98	98 (93 to 99)
	90[h]	Abbott Architect	Anti-N-IgG	8	82	91 (83 to 95)
	100	SD RDT IgM	Anti-N-IgM	9	91	91 (84 to 95)
	100	SD RDT IgG	Anti-N-IgG	1	99	99 (94 to 100)
Patients in whom a separate whole blood specimen was positive for malaria by PCR within the same 14 days (NRCP, area where malaria is not endemic)[d]	143	cPass	Anti-RBD blocking Ab, all subclasses	1	142	99 (96 to 100)
	142[i]	Abbott Architect	Anti-N-IgG	6	136	96 (91 to 98)
	143	SD RDT IgM	Anti-N-IgM	12	131	92 (86 to 95)
	143	SD RDT IgG	Anti-N-IgG	4	139	97 (93 to 99)
Visceral leishmaniasis[d]	5	cPass	Anti-RBD blocking Ab, all subclasses	0	5	100 (46 to 100)
	5	Abbott Architect	Anti-N-IgG	0	5	100 (46 to 100)
	5	SD RDT IgM	Anti-N-IgM	0	5	100 (46 to 100)
	5	SD RDT IgG	Anti-N-IgG	1	4	80 (30 to 99)
Human African trypanosomiasis[d]	42	cPass	Anti-RBD blocking Ab, all subclasses	1	41	98 (88 to 99)
	42	Abbott Architect	Anti-N-IgG	5	37	88 (75 to 95)
	42	SD RDT IgM	Anti-N-IgM	2	40	95 (84 to 99)
	42	SD RDT IgG	Anti-N-IgG	0	42	100 (89 to 100)
T. cruzi seropositivity	49	cPass	Anti-RBD blocking Ab, all subclasses	0	49	100 (91 to 100)
	49	Abbott Architect	Anti-N-IgG	0	49	100 (93 to 100)
	49	SD RDT IgM	Anti-N-IgM	0	49	100 (93 to 100)
	49	SD RDT IgG	Anti-N-IgG	4	45	92 (81 to 97)
Overall protozoan parasitic infections (malaria/leishmaniasis/trypanosomiasis)	339	cPass	Anti-RBD blocking Ab, all subclasses	4	335	99 (97 to 99)
	328	Abbott Architect	Anti-N-IgG	19	309	94 (91 to 96)
	339	SD RDT IgM	Anti-N-IgM	23	316	93 (90 to 95)
	339	SD RDT IgG	Anti-N-IgG	10	329	97 (95 to 98)
S. stercoralis seropositivity	50	cPass	Anti-RBD blocking Ab, all subclasses	2	48	96 (86 to 99)
	50	Abbott Architect	Anti-N-IgG	1	49	98 (89 to 100)
	50	SD RDT IgM	Anti-N-IgM	1	49	98 (89 to 100)
	50	SD RDT IgG	Anti-N-IgG	1	49	98 (89 to 100)
Schistosoma sp. seropositivity	40	cPass	Anti-RBD blocking Ab, all subclasses	1	39	97 (87 to 99)
	40	Abbott Architect	Anti-N-IgG	2	38	95 (83 to 99)
	40	SD RDT IgM	Anti-N-IgM	3	37	92 (80 to 97)
	40	SD RDT IgG	Anti-N-IgG	1	39	97 (87 to 99)
Filaria sp. seropositivity	40	cPass	Anti-RBD blocking Ab, all subclasses	2	38	95 (83 to 99)
	40	Abbott Architect	Anti-N-IgG	3	37	92 (80 to 97)
	40	SD RDT IgM	Anti-N-IgM	2	38	95 (83 to 99)
	40	SD RDT IgG	Anti-N-IgG	2	38	95 (83 to 99)
Trichinellosis (*Trichinella* sp.)[d]	30	cPass	Anti-RBD blocking Ab, all subclasses	0	30	100 (86 to 100)
	30	Abbott Architect	Anti-N-IgG	1	29	97 (83 to 99)
	30	SD RDT IgM	Anti-N-IgM	1	29	97 (83 to 99)
	30	SD RDT IgG	Anti-N-IgG	1	29	97 (83 to 99)

(Continued on next page)

TABLE 2 (Continued)

Pre-COVID specimen origin	No.	Assay	Analyte detected	FP[a]	TN[b]	Specificity (95% CI) (%)[c]
Overall helminth infections (strongyloidiais/schistosomiasis/filariasis/trichinellosis)	160	cPass	Anti-RBD blocking Ab, all subclasses	5	155	97 (93 to 99)
	160	Abbott Architect	Anti-N-IgG	7	153	96 (91 to 98)
	160	SD RDT IgM	Anti-N-IgM	7	153	96 (91 to 98)
	160	SD RDT IgG	Anti-N-IgG	5	155	97 (93 to 99)
Sera from parasite suspects negative for all above diseases	60	cPass	Anti-RBD blocking Ab, all subclasses	1	59	98 (91 to 100)
	60	Abbott Architect	Anti-N-IgG	0	60	100 (92 to 100)
	60	SD RDT IgM	Anti-N-IgM	0	60	100 (94 to 100)
	60	SD RDT IgG	Anti-N-IgG	0	60	100 (94 to 100)
Overall (all samples)	559	cPass	Anti-RBD blocking Ab, all subclasses	10	549	98 (97 to 99)
	548	Abbott Architect	Anti-N-IgG	26	522	95 (93 to 97)
	559	SD RDT IgM	Anti-N-IgM	30	529	95 (92 to 96)
	559	SD RDT IgG	Anti-N-IgG	15	544	97 (96 to 98)

[a]FP, false positive.
[b]TN, true negative.
[c]Wilson score interval binomial 95% confidence intervals (CI) presented with Yate's continuity correction applied as appropriate.
[d]These specimens were drawn from patients clinically suspected of active disease for the purpose of diagnosis, as opposed to screening of asymptomatic individuals.
[e]The cutoff used to determine cPass positivity was ≥30% inhibition. The cutoff used to determine Abbott Architect positivity was a sample-to-stored calibrator index (S/C) of >1.4.
[f]RBD, receptor-binding domain.
[g]Ab, antibody.
[h]The results were unavailable for 10 of 100 specimens due to insufficient volume.
[i]The results were unavailable for 1 of 143 specimens due to insufficient volume.

(Fig. 2B); or cPass, Abbott Architect, and SD RDT IgG or SD RDT IgM (Fig. 2C), all three assays were in agreement for only 14% (5 of 36), 7.8% (4 of 51), or 8.3% (5 of 60) of the false-positive results, respectively. When comparing SD RDT IgG and SD RDT IgM (Fig. 2D), the two assays were in agreement for 15% (6 of 39) of the specimens with a false-positive result.

Readout intensities of each serological test were assembled in a heat map for specimens with false-positive results from one or more tests (Fig. 3). Overall, among specimens with false-positive results, there was very little correlation between the signal intensity of a false-positive test result and the probability of a false positive with another assay. Strong signal intensities were common among false-positive results from laboratory-based assays. The cPass yielded positive results for 10 of 60 (16.7%) specimens with false-positive results from one or more tests, with 5 of these having a binding inhibition of >50%. The Abbott Architect yielded positive results for 26 of 60 (43.3%) false-positive specimens, with 17 of these having sample-to-stored calibrator index (S/C) of >1.68, which we considered strong positives. In contrast, weak or very weak signal intensity was common for the false-positive results observed with the SD RDT. SD RDT IgG was positive among 16 of 60 (36.7%) false-positive specimens, with 5 of these having barely visible but present bands. In contrast, SD RDT IgM was positive for 30 of 60 (50%) false-positive specimens, with 20 of these having barely visible but present bands. All but one of the other positive SD RDT IgM results were considered weak.

DISCUSSION

We sought to assess the specificity of three SARS-CoV-2 antibody detection assays among people who were either ill with microbiologically proven malaria or seropositive for other tissue-borne parasitic infections. We tested assays against either the S or the N protein, among a large collection of well-characterized pre-COVID-19 sera from clinical suspects with relevant tropical infectious diseases that may lead to cross-reactions with SARS-CoV-2 serologic assays. Previous reports found increased frequency of nonspecific binding leading to positive results in smaller cohorts of patients with and without recent malaria in Nigeria (11), Benin (12), and Tanzania and Zambia (13). We confirm these findings with different serological assays and extend them to patients with imported malaria residing in an area where malaria is not endemic, as well as to patients with several key tropical infectious diseases for which there is a

TABLE 3 Relative risk of false-positive result by assay and target analyte, according to specimen origin

Pre-COVID specimen origin	No.	Assay	Analyte detected	FP	TN	Risk ratio (95% CI)
Confirmed active or recent malaria by microscopy or RDT (Senegal, area where malaria is endemic)[a]	90	Abbott Architect	Anti-N-IgG	8	82	4.44 (0.97 to 20.38)
	100	SD RDT IgM	Anti-N-IgM	9	91	4.50 (0.997 to 20.31)
	100	SD RDT IgG	Anti-N-IgG	1	99	0.50 (0.05 to 5.43)
	100	cPass[b]	Anti-RBD blocking Ab, all subclasses	2	98	Ref.[c]
Patients in whom a separate whole blood specimen was positive for malaria by PCR within the same 14 days (NRCP, area where malaria is not endemic)[a]	142	Abbott Architect	Anti-N-IgG	6	136	6.04 (0.74 to 49.55)
	143	SD RDT IgM	Anti-N-IgM	12	131	12.00 (1.58 to 91.07)
	143	SD RDT IgG	Anti-N-IgG	4	139	4.00 (0.45 to 35.35)
	143	cPass	Anti-RBD blocking Ab, all subclasses	1	142	Ref.
Overall malaria (Senegal and NRCP)	232	Abbott Architect	Anti-N-IgG	14	218	4.89 (1.42 to 16.79)
	243	SD RDT IgM	Anti-N-IgM	21	222	7.00 (2.11 to 23.16)
	243	SD RDT IgG	Anti-N-IgG	5	238	1.67 (0.40 to 6.90)
	243	cPass[a]	Anti-RBD blocking Ab, all subclasses	3	240	Ref.
Visceral leishmaniasis[a]	5	Abbott Architect	Anti-N-IgG	0	5	
	5	SD RDT IgM	Anti-N-IgM	0	5	
	5	SD RDT IgG	Anti-N-IgG	1	4	
	5	cPass	Anti-RBD blocking Ab, all subclasses	0	5	Ref.
Human African trypanosomiasis[a]	42	Abbott Architect	Anti-N-IgG	5	37	5.00 (0.61 to 40.99)
	42	SD RDT IgM	Anti-N-IgM	2	40	2.00 (0.19 to 21.22)
	42	SD RDT IgG	Anti-N-IgG	0	42	0
	42	cPass	Anti-RBD blocking Ab, all subclasses	1	41	Ref.
T. cruzi seropositivity	49	Abbott Architect	Anti-N-IgG	0	49	
	49	SD RDT IgM	Anti-N-IgM	0	49	
	49	SD RDT IgG	Anti-N-IgG	4	45	
	49	cPass	Anti-RBD blocking Ab, all subclasses	0	49	Ref.
Overall protozoan parasitic infections (malaria/leishmaniasis/trypanosomiasis)	328	Abbott Architect	Anti-N-IgG	19	309	4.91 (1.69 to 14.28)
	339	SD RDT IgM	Anti-N-IgM	23	316	5.75 (2.01 to 16.45)
	339	SD RDT IgG	Anti-N-IgG	10	329	2.50 (0.79 to 7.89)
	339	cPass	Anti-RBD blocking Ab, all subclasses	4	335	Ref.
S. stercoralis seropositivity	50	Abbott Architect	Anti-N-IgG	1	49	0.50 (0.05 to 5.34)
	50	SD RDT IgM	Anti-N-IgM	1	49	0.50 (0.05 to 5.34)
	50	SD RDT IgG	Anti-N-IgG	1	49	0.50 (0.05 to 5.34)
	50	cPass	Anti-RBD blocking Ab, all subclasses	2	48	Ref.
Schistosoma sp. seropositivity	40	Abbott Architect	Anti-N-IgG	2	38	2.00 (0.19 to 21.18)
	40	SD RDT IgM	Anti-N-IgM	3	37	3.00 (0.32 to 27.63)
	40	SD RDT IgG	Anti-N-IgG	1	39	1.00 (0.06 to 15.44)
	40	cPass	Anti-RBD blocking Ab, all subclasses	1	39	Ref.
Filaria sp. seropositivity	40	Abbott Architect	Anti-N-IgG	3	37	1.50 (0.26 to 8.50)
	40	SD RDT IgM	Anti-N-IgM	2	38	1.00 (0.15 to 6.75)
	40	SD RDT IgG	Anti-N-IgG	2	38	1.00 (0.15 to 6.75)
	40	cPass	Anti-RBD blocking Ab, all subclasses	2	38	Ref.
Trichinellosis (*Trichinella* sp.)[a]	30	Abbott Architect	Anti-N-IgG	1	29	
	30	SD RDT IgM	Anti-N-IgM	1	29	
	30	SD RDT IgG	Anti-N-IgG	1	29	
	30	cPass	Anti-RBD blocking Ab, all subclasses	0	30	Ref.

(Continued on next page)

TABLE 3 (Continued)

Pre-COVID specimen origin	No.	Assay	Analyte detected	FP	TN	Risk ratio (95% CI)
Overall helminth infections (strongyloidiais/ schistosomiasis/filariasis/trichinellosis)	160	Abbott Architect	Anti-N-IgG	7	153	1.40 (0.45 to 4.32)
	160	SD RDT IgM	Anti-N-IgM	7	153	1.40 (0.45 to 4.32)
	160	SD RDT IgG	Anti-N-IgG	5	155	1.00 (0.29 to 3.39)
	160	cPass	Anti-RBD blocking Ab, all subclasses	5	155	Ref.
Sera from parasite suspects negative for all above pathogens	60	Abbott Architect	Anti-N-IgG	0	60	
	60	SD RDT IgM	Anti-N-IgM	0	60	
	60	SD RDT IgG	Anti-N-IgG	0	60	
	60	cPass	Anti-RBD blocking Ab, all subclasses	1	59	Ref.
Overall (all samples)	548	Abbott Architect	Anti-N-IgG	26	522	2.65 (1.29 to 5.45)
	559	SD RDT IgM	Anti-N-IgM	30	529	3.00 (1.48 to 6.08)
	559	SD RDT IgG	Anti-N-IgG	15	544	1.50 (0.68 to 3.31)
	559	cPass	Anti-RBD blocking Ab, all subclasses	10	549	Ref.

[a]These specimens were drawn from patients clinically suspected of active disease for the purpose of diagnosis, as opposed to screening of asymptomatic individuals.
[b]The cutoff used to determine cPass positivity was ≥30% inhibition. The cutoff used to determine Abbott Architect positivity was a sample-to-stored calibrator index (S/C) of >1.4.
[c]Ref., Reference.

current void of available information on which to base interpretation of serological results for SARS-CoV-2.

The observed specificity of all assays ranged from 95 to 98% in the overall group of specimens. However, those for the Abbott Architect (95% [95% CI, 93 to 97]) and the SD RDT IgM (95% [95% CI, 93 to 96]) fell short of the World Health Organization-recommended 97% benchmark for SARS-CoV-2 serological assays (14). Moreover, these values are well below esti- mates for the Abbott Architect from previous data among specimens from high-income coun- tries, including 99.6% reported by the manufacturer using a panel of pre-COVID-19 specimens


FIG 2 Venn diagram comparing false-positive results from cPass, Abbott Architect, SD RDT IgG, and SD RDT IgM serology from patients with protozoan and helminth parasites infections. (A to C) Overlap of cPass and Abbott Architect with SD RDT IgG, SD RDT IgM, or any positive SD RDT result, respectively. (D) Overlap of SD RDT IgG and SD RDT IgM. The numbers denote the number of false-positive specimens in each category. RDT, rapid diagnostic test.

Pre-COVID specimen origin	Specimen number	cPass % inhibition	Abbott Signal-to-cutoff ratio	SD RDT IgG band intensity	SD RDT IgM band intensity
Confirmed active or recent malaria by microscopy or RDT (Senegal -endemic area)	#1	6.57	1.03	0	0
	#2	0.28	1.14	0	0
	#3	-0.89	1.26	0	0
	#4	11.09	0.31	0	2
	#5	7.85	0.26	0	1
	#6	5.26	2.95	0	0
	#7	5.81	0.07	0	1
	#8	4.26	0.51	0	1
	#9	-10.00	1.37	0	0
	#10	-7.20	0.13	0	1
	#11	4.30	0.21	0	1
	#12	9.04	1.42	0	0
	#13	-0.98	0.31	0	1
	#14	-9.19	0.26	0	1
	#15	31.52	0.66	0	2
	#16	55.52	3.29	3	0
	#17	28.46	1.52	0	0
Patients in whom a separate whole blood specimen was positive for malaria by PCR within the same 14 days (NRCP -non-endemic area)	#18	30.90	0.68	0	0
	#19	-14.18	1.05	0	0
	#20	7.97	1.08	0	0
	#21	10.59	1.02	0	0
	#22	29.07	0.12	1	0
	#23	11.38	1.31	0	2
	#24	18.13	0.45	0	2
	#25	3.91	0.26	0	1
	#26	-17.52	0.09	2	0
	#27	11.95	0.11	0	2
	#28	10.01	0.21	0	1
	#29	22.43	1.09	0	0
	#30	-8.15	0.07	0	1
	#31	-9.05	0.61	2	1
	#32	2.86	0.14	0	1
	#33	-9.47	0.14	0	1
	#34	28.77	1.26	3	1
	#35	-8.48	0.31	0	1
	#36	-7.49	0.11	0	1
Visceral leishmaniasis	#37	-2.35	0.11	3	0
Human African trypanosomiasis	#38	6.73	1.92	0	2
	#39	11.93	1.32	0	0
	#40	39.10	0.62	0	1
	#41	5.12	1.04	0	0
	#42	11.63	1.02	0	0
	#43	3.60	1.39	0	0
Human American trypanosomiasis	#44	6.40	0.19	2	0
	#45	10.30	0.21	2	0
	#46	-5.36	0.07	1	0
	#47	-10.72	0.06	1	0
Strongyloidiasis	#48	33.42	0.10	0	0
	#49	94.12	5.32	3	2
Schistosomiasis	#50	12.40	1.49	0	0
	#51	50.30	1.69	2	2
	#52	15.99	0.04	0	1
	#53	5.51	0.09	0	1
Filariasis	#54	21.89	1.13	0	0
	#55	50.40	1.84	3	2
	#56	67.92	2.96	1	3
Trichinellosis	#57	5.76	0.05	0	1
	#58	22.57	0.02	1	0
	#59	5.88	3.77	0	0
Sera from parasite-suspects negative for all above diseases	#60	31.61	0.04	0	0

cPass	Negative: <20% inhibition	-	Indeterminate: 20 to <30% inhibition	Positive: ≥30% inhibition
Abbott Architect	Negative: signal-to-cut-off ratio <1.0	-	Weak positive: signal-to-cut-off ratio 1.0 to 1.2	Strong positive: signal-to-cut-off ratio >1.2
SD RDT band intensity	No signal: Indicated by 0	Barely visible but present: Indicated by 1	Low intensity (faint but definitively positive): Indicated by 2	Medium to high intensity: Indicated by 3

FIG 3 Heat map of readout signal intensity of all false-positive specimens identified using three commercial serological assays for the detection of SARS-CoV-2. The cutoffs used to determine cPass positivity were as

(Continued on next page)

or from patients positive for alternative respiratory pathogens ($n = 1,070$) (15) and 99.6% reported in an independent evaluation of 1,099 pre-COVID-19 specimens (16). Similarly, the values for the SD RDT IgM are lower than the 100% specificity reported in the FDA serology test evaluation report for the Standard Q COVID-19 IgM/IgG combo rapid test (17).

As expected, the lowest observed specificities were seen among sera from patients with protozoan infections of the reticuloendothelial system, such as human African trypanosomiasis (Abbott Architect; 88% [95% CI, 75 to 95]) and visceral leishmaniasis (SD RDT IgG; 80% [95% CI, 30 to 99]), and from patients with recent malaria from an area of Senegal where malaria is holoendemic (ranging from 91% for Abbott Architect and SD RDT IgM to 98 to 99% for cPass and SD RDT IgG). Nonspecific cross-reaction among patients in areas where malaria is endemic may be potentiated by coinfections rather than from malaria infections alone. Alternatively, repeated infections with *Plasmodium* species rather than coinfections with other organisms may lead to a greater cross-reactivity. This is consistent with the association between false-positive SARS-CoV-2 results and the presence of anti-*Plasmodium* antibodies (11), as well as the relatively higher specificity observed in our cohort of patients with antibodies to tissue-invasive helminths. Specificities among sera positive for the presence of antibodies to *T. cruzi* ranged from 92% [95% CI, 81 to 97] (SD RDT IgG) to 100% [95% CI, 93 to 100] (all other assays). Taken as a whole, the observed specificities among the assays and specimens tested are likely adequate for serosurveys and epidemiologic tracking but below the threshold required for individual patient care decisions (1, 14).

In order to allow statistical comparisons between different SARS-CoV-2 diagnostic assays, we computed the relative risk of a false-positive result by diagnostic assay and target analyte, according to specimen origin (Table 3). The cPass showed the least variation across specimen origins and consistently had the highest specificity across groups. This assay was designed as a surrogate viral neutralization assay and measures the strength of inhibition of RDB binding to ACE-2 by host antibodies of any subclass. Perhaps surprisingly for a lateral flow immunochromatographic SARS-CoV-2 assay, the SD RDT IgG also showed very high performance across groups. Using cPass as the reference value, SD RDT IgG had a lower relative risk (RR) of a false-positive result than either SD RDT IgM or Abbott Architect. The latter two tests were statistically significantly more likely to yield false-positive results than the cPass for specimens with evidence of protozoan infections overall but not for specimens with evidence of tissue-invasive helminth infections. We previously showed that cPass has marginal advantages over anti-RBD IgG enzyme-linked immunosorbent assay (ELISA) (18). In this case, the SD RDT IgG detects anti-N IgG and performed comparably to a sophisticated surrogate viral neutralization assay. Moreover, it compared favorably to the laboratory-based Abbott Architect in this group of specimens of interest. This is relevant to low-resource tropical settings where central laboratory capacity frequently limits care of patients with fever syndromes (19).

The finding of very low categorical agreement between SARS-CoV-2 serological assays among specimens with a false-positive result is consistent with nonspecific binding between host antibodies and test antigens. This observation can be leveraged to design testing algorithms with increased specificity. In our specimen set, requiring a positive result from a second test among cPass, Abbott Architect, or SD RDT IgG would rule out the majority of false-positive results obtained after a first positive result (Fig. 2 and Table 4). Others have proposed an avidity assay using various concentrations of urea washes to prevent nonspecific binding (11), but this approach may not be suitable in low-resource settings, even when centralized laboratories exist.

FIG 3 Legend (Continued)
follows: negative was <20% inhibition; indeterminate was 20 to <30% inhibition; and positive was ≥30% inhibition. The criteria used to determine Abbott Architect signal strength were as follows: negative was a signal-to-cutoff ratio of <1.0; weak positive was a signal-to-cutoff ratio of 1.0 to 1.2; and strong positive was a signal-to-cutoff ratio of >1.2. In this case, the cutoff refers to the sample-to-stored calibrator index (S/C) cutoff value of 1.4, and a signal-to-cutoff ratio of 1.2 corresponds to an actual readout of $1.4 \times 1.2 = 1.68$. The categorization for SD RDT band intensity was as follows: a score of 0 indicates no signal; 1 indicates barely visible but present; 2 indicates low intensity (i.e., faint but definitively positive); and 3 indicates medium to high intensity. PCR, polymerase chain reaction; NRCP, National Reference Centre for Parasitology.

TABLE 4 Impact of performing sequential serologic assays on specificity for the detection of anti-SARS-CoV-2 antibodies[a]

Assay 1	Single-test Specificity (95% CI) (%)[b]	Assay 2	Combined specificity (95% CI) (%)[c]
cPass	99 (97 to 99)	Abbott Architect	100 (98 to 100)
		SD RDT IgG	100 (98 to 100)
Abbott Architect	94 (91 to 96)	cPass	100 (98 to 100)
		SD RDT IgG	99 (98 to 100)
SD RDT IgM[d]	93 (90 to 95)	cPass	99 (98 to 100)
		Abbott Architect	99 (97 to 100)
		SD RDT IgG	99 (98 to 100)
SD RDT IgG[d]	97 (95 to 98)	cPass	100 (98 to 100)
		Abbott Architect	99 (98 to 100)

[a]The diagnostic specificity of combinations of commercial serological assays for the detection of anti-SARS-CoV-2 antibodies was determined among all specimens positive for protozoan parasitic infections ($n = 339$). The order of the assays performed is accounted for in the combined specificity, because Assay 2 is only applied as a confirmatory test to specimens with a positive result by Assay 1.

[b]Wilson score interval binomial 95% confidence intervals presented.

[c]For the computation of combined specificities, positive results from both assays are required to determine a false positive. The order of assays performed is accounted for in the combined specificity, because Assay 2 is only applied as a confirmatory test to specimens with a positive result by Assay 1.

[d]SD RDT IgM results are not considered as results from Assay 2 because using the presence of IgM antibodies to confirm the presence of specific IgG antibodies is not felt to be a meaningful use case.

Limitations of our study include the fact that the available volume of stored prepandemic specimens precluded the possibility of performing specific avidity testing or assessing for the presence of antibodies to seasonal coronaviruses that may have cross-reacted with the SARS-CoV-2 serological assays. However, a report from the United States found no false positives for Abbott Architect or SD RDT IgM/IgG among 21 patients with recent seasonal coronavirus infections: NL63 ($n = 11$), HKU1 ($n = 7$), and 229E ($n = 3$) (20). Moreover, the fact that our data recapitulate findings from previous studies in areas where malaria is endemic is reassuring regarding their robustness.

Conclusions. Among sera from patients with tissue-borne parasitic infections, the specificity of SARS-CoV-2 serological assays was below the threshold required for decisions about individual patient care. Specificity is markedly increased by the use of confirmatory testing with a second assay. Finally, the SD RDT IgG proved similarly specific to laboratory-based assays and provides an option in low-resource settings when detection of anti-SARS-CoV-2 IgG is indicated.

REFERENCES

1. Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, Caya C, Semret M, Quach C, Libman M, Mazzola L, Sacks JA, Dittrich S, Papenburg J. 2020. Serodiagnostics for severe acute respiratory syndrome-related coronavirus 2: a narrative review. Ann Intern Med 173:450–460. https://doi.org/10.7326/M20-2854.

2. Van Caeseele P, Bailey D, Forgie SE, Dingle TC, Krajden M, COVID-19 Immunity Task Force. 2020. SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health. CMAJ 192:E973–E979. https://doi.org/10.1503/cmaj.201588.

3. Lejon V, Ngoyi DM, Ilunga M, Beelaert G, Maes I, Büscher P, Fransen K. 2010. Low specificities of HIV diagnostic tests caused by *Trypanosoma brucei gambiense* sleeping sickness. J Clin Microbiol 48:2836–2839. https://doi.org/10.1128/JCM.00456-10.

4. Gillet P, Mumba Ngoyi D, Lukuka A, Kande V, Atua B, van Griensven J, Muyembe JJ, Jacobs J, Lejon V. 2013. False positivity of non-targeted infections in malaria rapid diagnostic tests: the case of human African trypanosomiasis. PLoS Negl Trop Dis 7:e2180. https://doi.org/10.1371/journal.pntd.0002180.

5. Shanks L, Ritmeijer K, Piriou E, Siddiqui MR, Kliescikova J, Pearce N, Ariti C, Muluneh L, Masiga J, Abebe A. 2015. Accounting for false positive HIV tests: is visceral leishmaniasis responsible? PLoS One 10:e0132422. https://doi.org/10.1371/journal.pone.0132422.

6. Ly A, Hansen DS. 2019. Development of B cell memory in malaria. Front Immunol 10:559. https://doi.org/10.3389/fimmu.2019.00559.

7. Silveira ELV, Dominguez MR, Soares IS. 2018. To B or not to B: understanding B cell responses in the development of malaria infection. Front Immunol 9:2961. https://doi.org/10.3389/fimmu.2018.02961. https://doi.org/10.3389/fimmu.2018.02961.

8. Rahumatullah A, Balachandra D, Noordin R, Baharudeen Z, Lim YY, Choong YS, Lim TS. 2021. Broad specificity of immune helminth scFv library to identify monoclonal antibodies targeting *Strongyloides*. Sci Rep 11:2502. https://doi.org/10.1038/s41598-021-82125-3.

9. World Health Organization. 2020. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. World Health Organization, Geneva, Switzerland.

10. World Health Organization. 2020. World malaria report 2020: 20 years of global progress and challenges. World Health Organization, Geneva, Switzerland.

11. Steinhardt LC, Ige F, Iriemenam NC, Greby SM, Hamada Y, Uwandu M, Aniedobe M, Stafford KA, Abimiku A, Mba N, Agala N, Okunoye O, Mpamugo A, Swaminathan M, Onokevbagbe E, Olaleye T, Odoh I, Marston BJ, Okoye M, Abubakar I, Rangaka MX, Rogier E, Audu R. 2021. Cross-reactivity of two SARS-CoV-2 serological assays in a setting where malaria is endemic. J Clin Microbiol 59:e0051421. https://doi.org/10.1128/JCM.00514-21.

12. Yadouleton A, Sander AL, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, Fischer C, Krause N, Akogbeto P, de Oliveira Filho EF, Dossou A, Brünink S, Aïssi MAJ, Djingarey MH, Hounkpatin B, Nagel M, Drexler JF. 2021. Limited specificity of serologic tests for SARS-CoV-2 antibody detection, Benin. Emerg Infect Dis 27:233–237. https://doi.org/10.3201/eid2701.203281.

13. Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, Ngalamika O, Julius P, West JT, Wood C. 2021. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis 102:577–583. https://doi.org/10.1016/j.ijid.2020.10.104.

14. World Health Organization. 2020. Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0. World Health Organization, Geneva, Switzerland.

15. Abbott Laboratories. 2020. SARS-CoV-2 IgG for use with ARCHITECT package insert. Abbott Laboratories, Chicago, IL.

16. Patel EU, Bloch EM, Clarke W, Hsieh YH, Boon D, Eby Y, Fernandez RE, Baker OR, Keruly M, Kirby CS, Klock E, Littlefield K, Miller J, Schmidt HA, Sullivan P, Piwowar-Manning E, Shrestha R, Redd AD, Rothman RE, Sullivan D, Shoham S, Casadevall A, Quinn TC, Pekosz A, Tobian AAR, Laeyendecker O. 2021. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. J Clin Microbiol 59:e02257-20. https://doi.org/10.1128/JCM.02257-20.

17. SD BioSensor Inc. 2020. Serology test evaluation report for Standard Q COVID-19 IgM/IgG duo (updated June 21, 2020). SD BioSensor Inc, Gyeonggi-do, Republic of Korea.

18. Papenburg J, Cheng MP, Corsini R, Caya C, Mendoza E, Manguiat K, Lindsay LR, Wood H, Drebot MA, Dibernardo A, Zaharatos G, Bazin R, Gasser R, Benlarbi M, Gendron-Lepage G, Beaudoin-Bussières G, Prévost J, Finzi A, Ndao M, Yansouni CP. 2021. Evaluation of a commercial culture-free neutralization antibody detection kit for severe acute respiratory syndrome-related coronavirus-2 and comparison with an antireceptor-binding domain enzyme-linked immunosorbent assay. Open Forum Infect Dis 8:ofab220. https://doi.org/10.1093/ofid/ofab220.

19. Semret M, Ndao M, Jacobs J, Yansouni CP. 2018. Point-of-care and point-of-"can": leveraging reference-laboratory capacity for integrated diagnosis of fever syndromes in the tropics. Clin Microbiol Infect 24:836–844. https://doi.org/10.1016/j.cmi.2018.03.044.

20. Paiva KJ, Grisson RD, Chan PA, Huard RC, Caliendo AM, Lonks JR, King E, Tang EW, Pytel-Parenteau DL, Nam GH, Yakirevich E, Lu S. 2021. Validation and performance comparison of three SARS-CoV-2 antibody assays. J Med Virol 93:916–923. https://doi.org/10.1002/jmv.26341.

21. Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, Morrison TE, Huey L, Annen K, DomBourian MG, Knight V. 2021. A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection. J Clin Microbiol 59:e02438-20. https://doi.org/10.1128/JCM.02438-20.

22. Micallef L, Rodgers P. 2014. eulerAPE: drawing area-proportional 3-Venn diagrams using ellipses. PLoS One 9:e101717. https://doi.org/10.1371/journal.pone.0101717.